about
Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons LearnedA Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma CellsHippocampal and ventricular changes in Parkinson's disease mild cognitive impairmentMemantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's diseaseReliability of Three Disability Scales for Detection of Independence Loss in Parkinson's Disease.Epidemiology of psychosis in Parkinson's disease.Impulsive and Compulsive Behaviors in Parkinson's Disease: The Norwegian ParkWest Study.New insight into neurodegeneration: the role of proteomics.Parkinson's disease and age: The obvious but largely unexplored link.Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited.microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases.Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study.Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study.Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study.Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD.Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study.Risk and course of motor complications in a population-based incident Parkinson's disease cohort.Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population.The Arabidopsis DJ-1a protein confers stress protection through cytosolic SOD activation.Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study.Cigarette smoking in Parkinson's disease: influence on disease progression.Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease.Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration.Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.CSF Aβ42 predicts early-onset dementia in Parkinson disease.Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease.No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease.Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage.Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study.Gray matter correlations of cognition in incident Parkinson's disease.Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study.What predicts mortality in Parkinson disease?: a prospective population-based long-term study.A 12-year population-based study of psychosis in Parkinson disease.A 12-year population-based study of freezing of gait in Parkinson's disease.The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease.Predictors and course of health-related quality of life in Parkinson's disease.Brain atrophy and white matter hyperintensities in early Parkinson's disease(a).Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease.
P50
Q26738357-01B8D76A-E489-494B-A9F4-F76C9A226FE8Q28551285-E30C40C0-2144-4DE1-BC68-9B07DCD23842Q33829483-CA868082-3EC4-4694-9897-BBFA26B77599Q34018018-A1395A85-8F0F-45DE-B0A3-104B6653BDFFQ36718213-5EAAA7C7-3331-440E-A34E-8C9CBC466A9AQ36880831-A73E3135-4878-42A9-A2AE-9236DCCB6CA3Q37594256-271BD160-2E73-47A8-9326-F9843FEE0465Q37635622-997CD9F2-E967-43B1-85BB-96356E680BE5Q38170010-87A2C119-886C-43D2-95B4-F25116C9382BQ38254853-1927324C-58BF-4659-903A-3BCF4A68A525Q38498703-1A9AB055-D010-41E5-AF59-3DBFB03F43B0Q38648154-98048823-1E70-43FF-ACA0-BE07AE5586F3Q39079510-048CF203-B660-40FE-A7EA-6F89F2646FE2Q39427052-05140953-D947-4833-8BA6-4A8CA9D6045EQ39952638-E61A4FD8-556D-4707-A7BD-5986C39D8BE7Q40367571-E4BDB352-21CD-484D-ADC7-076B16959ADBQ40370637-06FA27A5-D9BD-4681-B0D8-F02D3DCD422CQ41112428-A7AA6690-9CEE-4078-A085-4AB32078C051Q42178133-F6CD0A88-11CA-4A15-B77A-1AB593F62B8CQ43091640-4AA05005-1858-4B46-958B-981EB5C7BBB3Q44803634-828EF26A-BE05-4A07-8BF8-49673F859A72Q45062603-69B7C947-9826-4E96-A76F-0CF307E5C28DQ46236554-59DE05A3-15E1-4F74-A3D0-ACD5117C4C50Q46460788-4B11F734-F723-4DE3-AADD-878477A141D1Q46554106-3692027B-B717-4F23-AE74-A22F7CBF27F8Q46663871-193AF7CA-0140-4BFA-BE16-D30012132DDDQ46802886-6D6EEE31-4238-4EBC-8944-F4A40EA1BA02Q47556023-F07ED06C-33FE-4D54-A583-8364EC513D44Q47572328-3AB69D8B-F4FD-4736-AEEA-B51CA3880F95Q48249857-D2AAEE06-4AA9-4974-B3F9-30F82F0AAD09Q48279033-38AAF430-FB07-4C8C-96B1-C4BD598D4E84Q48322397-33B48920-8B2C-4A30-B05E-12D5028F7DC0Q48337863-2944AA47-C470-4B19-AE59-FA20DE4F5EF6Q48345449-17F39C7C-9E5F-4E99-9E0F-16650EB47B3EQ48368406-D166C5D2-1576-4CEF-9D75-A9469FB9B7F0Q48394463-C6F6E7F7-2EA7-4AFF-9D40-31104A3EBC15Q48433831-6884C3B2-E65B-4FBA-AEA1-DA1BF451A790Q48454100-DA27A0CD-7551-450D-A988-617349021C4FQ48490629-88F8F172-3054-4F04-91C2-81DFC264F063Q48563553-7038381A-8147-469B-B554-FFCD3ED4338E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Guido Alves
@ast
Guido Alves
@en
Guido Alves
@es
Guido Alves
@nl
Guido Alves
@sl
type
label
Guido Alves
@ast
Guido Alves
@en
Guido Alves
@es
Guido Alves
@nl
Guido Alves
@sl
altLabel
Alves G
@en
prefLabel
Guido Alves
@ast
Guido Alves
@en
Guido Alves
@es
Guido Alves
@nl
Guido Alves
@sl
P106
P1153
57189684487
7006053906
P21
P31
P4012
P496
0000-0003-0630-2870